Abstract: Novel aminoazetidine, -pyrrolidine, and -piperidine derivatives, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
June 22, 2001
Date of Patent:
May 13, 2003
Novo Nordisk A/S
Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
Abstract: Described is an electronic injection device wherein an electronic circuit is designed to work in two alternative modes: an air shot mode and a dose injection mode. When working in the air shot mode a small predetermined air shot dose is pressed out from the ampule when the injection button is actuated. When working in the injection mode, a dose set by operation of the dose setting means is injected by operation of the injection button. The electronic injection device is normally working in the air shot mode but shifts to work in the dose injection mode when it receives a signal indicating that the dose setting means has been operated. The circuit returns to its air shot mode when receiving a signal indicating that the set dose has been injected. This signal can originate either from a switch indicating that the protection cap is mounted or from a switch indicating that the injection button has been pressed.
September 28, 2000
Date of Patent:
February 4, 2003
Novo Nordisk A/S
Jens Munk, Denmark Denmark Aasmul, Henrik Ljunggreen, Lars Hofmann Christensen
Abstract: A medication delivery device comprising a container containing a fluid medicament. The medicament is expelled from the container by moving forward an elastomeric piston inside the cartridge. The piston is moved forward by a telescopic piston rod, which can either be centrally located in the container or eccentric located. One end of the telescopic piston rod abuts the elastomeric piston either by itself or through an additional plate. The abutment having a friction large enough to prevent a lower part of the telescopic rod from rotating. In order to prevent the elastomeric piston from rotating inside the container a second telescopic piston rod is provided parallel with the first telescopic piston rod.
Abstract: A flexible piston rod for an injection device, which piston has the form of a helical spring made from a number of narrowly adjacent turns of windings. These turns provide an external thread fitting into the internal thread of a nut element. When the nut element is rotated, the piston rod is advanced forward, which movement is used to displace a piston inside a cartridge containing a fluid to be expelled. In order to prevent the piston rod from rotating when the nut element is rotated, the helical spring making up the piston rod is provided with a longitudinal spine, which is located at a peripheral area of the helical spring.
Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.